2012至2018年美国烧伤后加巴喷丁类药物伴或不伴阿片类药物的处方情况
该研究为2012至2018年成人烧伤患者的人群水平队列研究,评估加巴喷丁类药物伴或不伴阿片类药物的处方率及决定因素。在98,001例烧伤患者中,22,521例(22.98%)接受了阿片类药物和/或加巴喷丁类药物。加巴喷丁类药物处方占比从2012年的2.4%增至2018年的7.2%,加巴喷丁类药物-阿片类药物联合处方从2.3%增至5.1%。
要点
- 98,001例烧伤患者中22,521例(22.98%)接受阿片类和/或加巴喷丁类药物。
- 加巴喷丁类药物处方占比从2012年2.4%升至2018年7.2%。
- 加巴喷丁类药物-阿片类联合处方从2012年2.3%升至2018年5.1%。
核心结论
- 2014和2016年指南发布后,烧伤患者门诊加巴喷丁类药物处方适度增加,提示处方者有更多机会扩大非阿片类疼痛管理。
研究设计与样本
- 研究为2012至2018年成人烧伤患者的人群水平队列研究,共纳入98,001例烧伤患者,评估加巴喷丁类药物伴或不伴阿片类药物的处方率及决定因素。
主要发现
- 98,001例烧伤患者中,22,521例(22.98%)接受了阿片类药物和/或加巴喷丁类药物。
- 加巴喷丁类药物处方占比从2012年的2.4%增加至2018年的7.2%。
- 加巴喷丁类药物-阿片类药物联合处方从2012年的2.3%增加至2018年的5.1%。
- 50-65岁或居住在南部的患者加巴喷丁类药物处方增长率更高。
- 校正后,2017和2018年加巴喷丁类药物处方可能性比2012和2013年高44%,阿片类药物处方可能性低38%,联合处方无统计学显著变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn injury pain manifests as a combination of inflammatory, nociceptive, and neuropathic features. While opioids are the mainstay of burn pain management, non-opioid medications, such as gabapentinoids, have also been considered as they target the central nervous system. Increased opioid adverse events and overdose deaths in the United States led to the 2014 and 2016 guidelines to reduce opioid prescribing and consider alternatives, such as gabapentinoids. In the context of burn, the rate of gabapentinoid prescribing at the national level is unknown and it is unclear whether any shift has occurred in prescribing practices over time. We conducted a population level cohort study of adult burn patients from 2012 to 2018 to evaluate the rates and determinants of gabapentinoid prescribing, with and without opioids. Of 98,001 patients with burn, 22,521 (22.98%) received opioids and/or gabapentinoids (GABA). GABA represented 2.4% of prescriptions in 2012, but increased to 7.2% by 2018, while GABA-opioid co-prescriptions increased from 2.3% to 5.1%. The rate of increase in GABA prescriptions was higher for those aged 50-65 years or residing in the South. After adjustment, GABA was 44% more likely to be prescribed in 2017 and 2018 compared to 2012 and 2013, opioids were 38% less likely, while co-prescribing did not show a statistically significant change. Our study showed a modest increase in gabapentinoids' outpatient prescribing for burn patients after the 2014 and 2016 guidelines, indicating more opportunities for prescribers to expand non-opioid pain management in this population.
引用
- Polychronopoulou E, Kuo YF, Wilkes D, et al. Prescribing of Gabapentinoids with or without opioids after burn injury in the US, 2012-2018. Burns. 2021. PMID: 34991930. doi:10.1016/j.burns.2021.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。